Lindbrook Capital, LLC Crinetics Pharmaceuticals, Inc. Transaction History
Lindbrook Capital, LLC
- $1.09 Billion
- Q4 2024
A detailed history of Lindbrook Capital, LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Lindbrook Capital, LLC holds 337 shares of CRNX stock, worth $11,441. This represents 0.0% of its overall portfolio holdings.
Number of Shares
337
Previous 363
7.16%
Holding current value
$11,441
Previous $18,000
5.56%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding CRNX
# of Institutions
255Shares Held
89.5MCall Options Held
26.1KPut Options Held
11.8K-
Vanguard Group Inc Valley Forge, PA9.09MShares$309 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA6.95MShares$236 Million0.07% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$212 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.14MShares$208 Million3.06% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.41MShares$184 Million0.03% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $1.82B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...